Bepridil
-
Bepridil
structure -
-
CAS No:
64706-54-3
-
Formula:
C24H34N2O
-
Chemical Name:
Bepridil
-
Synonyms:
1-Pyrrolidineethanamine,β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-;β-[(2-Methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine;Bepridil;Org 5730;(±)-Bepridil;dl-Bepridil;99239-95-9;89035-90-5
-
Categories:
Active Pharmaceutical Ingredients > Circulatory System Drugs
-
CAS No:
Description
ChEBI: A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Solid
Bepridil is a tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl. It has a role as a vasodilator agent, an anti-arrhythmia drug, an antihypertensive agent and a calcium channel blocker. It is a tertiary amine and a member of pyrrolidines.|A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).|A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Characteristics
15.7
5.2
Solid
1.054 g/cm3
128
184 °C @ Press: 0.1 Torr
133.2ºC
nD20 1.5538
H2O: Slightly soluble
Toxicity
There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
99%
Drug Information
For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)|Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)|A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Rapidly and completely absorbed after oral administration.
Hepatic.
24-50 hours
Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
1978 CERM
Bepridil Use and Manufacturing
The new calcium antagonists, in order to inhibit the slow channel of calcium ions, selectively expand the coronary arteries, in addition, can inhibit the sodium and potassium ion channels, and thus have the characteristics of class I a, III and IV antiarrhythmic drugs. The half-life is up to 42h. It can be administered once a day. It is well tolerated and has less toxic and side effects. Mainly used for the prevention and treatment of angina pectoris, and can be used for arrhythmia, hypertension and coronary heart disease.
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:366.5
XLogP3:5.3
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:10
Exact Mass:366.267113712
Monoisotopic Mass:366.267113712
Topological Polar Surface Area:15.7
Heavy Atom Count:27
Complexity:382
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Learn More Other Chemicals
-
Bepridil hydrochloride
68099-86-5
-
Dronedarone
141626-36-0
-
Zofenopril calcium
81938-43-4
-
3-Bromo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one Formula
86499-96-9
-
Tirofiban hydrochloride monohydrate Formula
150915-40-5
-
Saxagliptin Formula
361442-04-8
-
Dapoxetine Structure
119356-77-3
-
Fasudil Structure
103745-39-7
-
What is 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester
167221-71-8
-
What is 3-[(2R,5S)-5-(4-Fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino)]][4-[trimethylsilyl]-oxy]phenyl]methyl]-1-oxo-5-[(trimethylsily)-oxy]pentyl]-4-phenyl-(4S)-2-oxazolidinone
272778-12-8